[fcb5af]: / literature / by_gene_clean / CIITA.tsv

Download this file

# pmid doi year title Hugo_Symbol
1 35106936 10.1002/cam4.4550 2022 SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups. CIITA
2 33777766 10.3389/fonc.2021.620435 2021 Case Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma. CIITA
3 34360767 10.3390/ijms22158001 2021 HTLV-1 Infection and Pathogenesis: New Insights from Cellular and Animal Models. CIITA
4 34925435 10.3389/fgene.2021.677650 2021 Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing. CIITA
5 32002294 10.1080/2162402X.2019.1683346 2020 Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression. CIITA
6 32555149 10.1038/s41408-020-0335-0 2020 CREBBP and STAT6 co-mutation and 16p13 and 1p36 loss define the t(14;18)-negative diffuse variant of follicular lymphoma. CIITA
7 32649887 10.1016/j.ccell.2020.06.002 2020 Immunogenomic Landscape of Hematological Malignancies. CIITA
8 32947237 10.1016/j.tranon.2020.100855 2020 Identification of clinical molecular targets for childhood Burkitt lymphoma. CIITA
9 30211726 10.1097/PAS.0000000000001154 2019 Cyclin D1-positive Mediastinal Large B-Cell Lymphoma With Copy Number Gains of CCND1 Gene: A Study of 3 Cases With Nonmediastinal Disease. CIITA
10 30540571 10.1097/PAS.0000000000001198 2019 Gray-zone Lymphoma Between cHL and Large B-Cell Lymphoma: A Histopathologic Series From the LYSA. CIITA
11 31292115 10.1182/blood.2019001126 2019 Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma. CIITA
12 31704289 10.1016/j.intimp.2019.105999 2019 Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. CIITA
13 31783769 10.1186/s12977-019-0498-6 2019 Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1. CIITA
14 29289361 10.1016/j.blre.2017.12.001 2018 The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies. CIITA
15 29857068 10.1016/j.jid.2018.04.038 2018 Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. CIITA
16 28479318 10.1016/j.jid.2017.04.010 2017 Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing. CIITA
17 26500140 10.1038/leu.2015.299 2016 FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas. CIITA
18 26758422 10.3109/10428194.2015.1135431 2016 A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. CIITA
19 26792751 10.1128/JVI.03000-15 2016 The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-κB by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein. CIITA
20 26850007 10.1002/gcc.22345 2016 Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies. CIITA
21 25393674 10.3109/10428194.2014.985673 2015 Structural genomic alterations in primary mediastinal large B-cell lymphoma. CIITA
22 25712539 10.1002/path.4522 2015 Recurrent genomic rearrangements in primary testicular lymphoma. CIITA
23 25713363 10.1073/pnas.1501199112 2015 Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. CIITA
24 26049756 10.1097/MOH.0000000000000155 2015 Genomic alterations underlying immune privilege in malignant lymphomas. CIITA
25 26135560 10.1097/PAS.0000000000000473 2015 Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. CIITA
26 26229090 10.1158/2159-8290.CD-15-0370 2015 Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma. CIITA
27 26314988 10.1038/bcj.2015.69 2015 Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. CIITA
28 26549456 10.1016/j.celrep.2015.10.008 2015 Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression. CIITA
29 26599546 10.1371/journal.pone.0139663 2015 Genomic Landscape of Primary Mediastinal B-Cell Lymphoma Cell Lines. CIITA
30 23449805 10.1128/JVI.00250-13 2013 Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis. CIITA
31 23789844 10.1111/imm.12136 2013 Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. CIITA
32 22532676 10.1128/JVI.06908-11 2012 Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3. CIITA
33 22808135 10.1371/journal.pone.0040332 2012 Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma. CIITA
34 23251452 10.1371/journal.pone.0051203 2012 New fusion transcripts identified in normal karyotype acute myeloid leukemia. CIITA
35 21345951 10.1128/JVI.02123-10 2011 Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression. CIITA
36 21368758 10.1038/nature09754 2011 MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. CIITA
37 21664896 10.1016/j.bcp.2011.05.026 2011 Epigenetic regulation of CIITA expression in human T-cells. CIITA
38 21822207 10.1038/modpathol.2011.116 2011 Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. CIITA
39 19081173 10.1016/j.exphem.2008.10.001 2009 Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL). CIITA
40 16239429 10.1182/blood-2005-04-1510 2006 Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. CIITA
41 14563641 10.1182/blood-2003-05-1491 2004 Regulation of MHC class II expression in human T-cell malignancies. CIITA
42 14973505 10.1038/sj.leu.2403315 2004 Defective class II transactivator expression in a B lymphoma cell line. CIITA
43 15384976 10.1111/j.1365-2141.2004.05151.x 2004 Loss of heterozygosity, a frequent but a non-exclusive mechanism responsible for HLA dysregulation in non-Hodgkin's lymphomas. CIITA
44 12738680 10.1182/blood-2002-08-2482 2003 BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. CIITA
45 12887826 NA 2003 [Cloning and biological activities of riboenzymes against major histocompatibility complex class II transactivator]. CIITA
46 12218125 10.4049/jimmunol.169.6.3085 2002 DNA alkylating agents alleviate silencing of class II transactivator gene expression in L1210 lymphoma cells. CIITA
47 10637510 10.1038/sj.onc.1203293 1999 Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5'-RACE and LA - PCR analyses of biopsy samples. CIITA
48 9352360 10.1093/intimm/9.10.1545 1997 Suppression of MHC class II expression by human class II trans-activator constructs lacking the N-terminal domain. CIITA
49 8666795 NA 1996 Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells. CIITA